SLC5A2 and diabetic kidney disease: Therefore, the combination of SGLT2 inhibition drugs and RAS inhibition drugs might contribute to further correction of increased intraglomerular pressure, leading to a delay in the development and progression of diabetic kidney disease.30, 31 Our results suggested that the use of RAS inhibition drugs might independently contribute to a further reduction in eGFRMDRD, followed by decreased intraglomerular pressure.